Author:
Armağan Coşkun,Üçüncü Egeli Tuğba,Akyıldız Can,Erdoğan Kadri Murat,Erdoğan Funda,Duman Nuray,Özkan Hasan
Reference28 articles.
1. 1. Bosma JF, Henkin RI, Christiansen RL, Herdt JR. Hypoplasia of the nose and eyes, hyposmia, hypogeusia, and hypogonadotrophic hypogonadism in two males. J Craniofac Genet Dev Biol. 1981;1(2):153-84.
2. 2. Ruprecht KW, Majewski F. [Familiary arhinia combined with peters' anomaly and maxilliar deformities, a new malformation syndrome (author's transl)]. Klin Monbl Augenheilkd. 1978;172(5):708-15.
3. 3. Gordon CT, Xue S, Yigit G, Filali H, Chen K, Rosin N, et al. De novo mutations in SMCHD1 cause Bosma arhinia microphthalmia syndrome and abrogate nasal development. Nat Genet. 2017;49(2):249-55. doi:10.1038/ng.3765
4. 4. Fuller AK, McCrary HC, Graham ME, Skirko JR. The Case of the Missing Nose: Congenital Arhinia Case Presentation and Management Recommendations. Ann Otol Rhinol Laryngol. 2020;129(7):645-8. doi:10.1177/0003489420909415
5. 5. Lemmers RJLF, van der Stoep N, Vliet PJV, Moore SA, San Leon Granado D, Johnson K, et al. SM. SMCHD1 mutation spectrum for facioscapulohumeral muscular dystrophy type 2 (FSHD2) and Bosma arhinia microphthalmia syndrome (BAMS) reveals disease-specific localisation of variants in the ATPase domain. J Med Genet. 2019;56(10):693-700. doi:10.1136/jmedgenet-2019-106168